Joo Hyuk Sohn

Summary

Affiliation: Yonsei University College of Medicine
Country: Korea

Publications

  1. pmc Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
    Minkyu Jung
    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
    PLoS ONE 7:e45127. 2012
  2. pmc S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
    Yong Wha Moon
    Yonsei Cancer Center, Divison of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei ro, Seodaemun gu, Seoul 120 752, Korea
    BMC Cancer 13:583. 2013
  3. pmc Multi-disciplinary treatment of a rare pelvic cavity ependymoma
    Hye Jin Hwang
    Department of Hemato Oncology, Yonsei University College of Medicine, 250 Seongsanno, Seodaemoon Gu, Seoul 120 752, Korea
    Yonsei Med J 48:719-22. 2007
  4. ncbi request reprint The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
    Se Hyun Kim
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 60:393-400. 2008
  5. doi request reprint Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
    Yong Wha Moon
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun gu, Seoul, 120 752, Korea
    Cancer Chemother Pharmacol 66:425-31. 2010
  6. doi request reprint Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial
    Jaeheon Jeong
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 70:77-81. 2010
  7. doi request reprint Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
    Young Joo Lee
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Head Neck 32:235-43. 2010
  8. ncbi request reprint A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features
    Beom Kyung Kim
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Oncol Rep 19:1525-31. 2008
  9. ncbi request reprint Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
    Hye Jin Choi
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun gu, Shinchon Dong 134, CPO Box 8044, Seoul 120 752, South Korea
    Cancer Chemother Pharmacol 61:309-13. 2008
  10. ncbi request reprint Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer
    Yong Wha Moon
    Yonsei Cancer Center, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, CPO Box 8044, Seoul 120 752, Korea
    Anticancer Res 29:4243-9. 2009

Collaborators

Detail Information

Publications27

  1. pmc Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
    Minkyu Jung
    Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
    PLoS ONE 7:e45127. 2012
    ..Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms...
  2. pmc S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
    Yong Wha Moon
    Yonsei Cancer Center, Divison of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei ro, Seodaemun gu, Seoul 120 752, Korea
    BMC Cancer 13:583. 2013
    ..This study evaluated the efficacy and safety of S-1 combined with docetaxel (SD) following doxorubicin plus cyclophosphamide (AC) as neoadjuvant therapy in patients with HER2-negative, stage II-III breast cancer...
  3. pmc Multi-disciplinary treatment of a rare pelvic cavity ependymoma
    Hye Jin Hwang
    Department of Hemato Oncology, Yonsei University College of Medicine, 250 Seongsanno, Seodaemoon Gu, Seoul 120 752, Korea
    Yonsei Med J 48:719-22. 2007
    ..The patient was free of cancer for 4 years following surgery. This is a rare case of extraneural ependymoma for which an in vitro chemosensitivity test was critical in determining the multidisciplinary approach for treatment...
  4. ncbi request reprint The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC
    Se Hyun Kim
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 60:393-400. 2008
    ..The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC...
  5. doi request reprint Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
    Yong Wha Moon
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun gu, Seoul, 120 752, Korea
    Cancer Chemother Pharmacol 66:425-31. 2010
    ..We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)...
  6. doi request reprint Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial
    Jaeheon Jeong
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 70:77-81. 2010
    ..Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure...
  7. doi request reprint Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer
    Young Joo Lee
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Head Neck 32:235-43. 2010
    ..Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU-cisplatin in locally advanced head and neck cancer...
  8. ncbi request reprint A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features
    Beom Kyung Kim
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    Oncol Rep 19:1525-31. 2008
    ..To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations...
  9. ncbi request reprint Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy
    Hye Jin Choi
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun gu, Shinchon Dong 134, CPO Box 8044, Seoul 120 752, South Korea
    Cancer Chemother Pharmacol 61:309-13. 2008
    ..The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer...
  10. ncbi request reprint Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer
    Yong Wha Moon
    Yonsei Cancer Center, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, CPO Box 8044, Seoul 120 752, Korea
    Anticancer Res 29:4243-9. 2009
    ..We retrospectively compared adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided and empirical chemotherapies for unresectable non-small cell lung cancer (NSCLC) in this case-control study...
  11. ncbi request reprint Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin
    A Rum Yoon
    Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, South Korea
    Hum Gene Ther 17:379-90. 2006
    ....
  12. ncbi request reprint Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer
    Joo Hyuk Sohn
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
    Cancer 109:1845-950. 2007
    ..A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited-disease small-cell lung cancer (LD-SCLC) to evaluate the efficacy and toxicity...
  13. doi request reprint Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma
    Joo Hyuk Sohn
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
    Oncology 76:1-9. 2009
    ..We performed a prospective trial of a transarterial administration of a radiopharmaceutical (166)Ho-chitosan complex in patients with single, large HCC...
  14. pmc Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
    Byoung Chul Cho
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
    BMC Cancer 8:8. 2008
    ....
  15. ncbi request reprint Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib
    Byoung Chul Cho
    Yonsei Cancer Center, Seoul, Korea
    J Clin Oncol 25:2528-33. 2007
    ..This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib...
  16. ncbi request reprint dl-VSVG-LacZ, a vesicular stomatitis virus glycoprotein epitope-incorporated adenovirus, exhibits marked enhancement in gene transduction efficiency
    Chae Ok Yun
    Institute for Cancer Research, Yonsei Cancer Center, Seodaemun gu, Seoul, South Korea
    Hum Gene Ther 14:1643-52. 2003
    ..Taken together, these studies demonstrate that the strategy to extend adenovirus tropism may greatly improve the utility of adenovirus in gene therapy applications...
  17. doi request reprint Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC
    Hye Jin Choi
    Division of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seodaemun gu shinchon dong 134, Seoul, Korea
    J Neurooncol 91:307-13. 2009
    ..Nevertheless, some subsets of patients manifested the most favorable survival criteria (single brain metastasis and good liver function); thus, for at least these patients, treatment may result in an improved survival time...
  18. ncbi request reprint Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer
    Yong Wha Moon
    Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, and Department of Division of Hemato Oncology, National Health Insurance Corp, Ilsan Hospital, Kyonggi Do, Korea
    Cancer 109:1829-35. 2007
    ..The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer (NSCLC)...
  19. doi request reprint A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results
    Hye Jin Choi
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 71:55-9. 2011
    ....
  20. doi request reprint Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
    Yong Wha Moon
    Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    J Cancer Res Clin Oncol 137:1123-30. 2011
    ..To evaluate prognostic factors in estrogen receptor (ER)-positive, operable breast cancer focusing on the progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)...
  21. doi request reprint Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02
    Yeon Hee Park
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon dong Gangnam gu, Seoul, Korea
    J Clin Oncol 31:1732-9. 2013
    ....
  22. pmc Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    Han Sang Kim
    Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Republic of Korea
    Support Care Cancer 21:1751-9. 2013
    ..We tested the effectiveness of standardized education and telemonitoring for improving pain, distress, anxiety, depression, quality of life (QoL), and performance in outpatients with advanced cancers...
  23. ncbi request reprint A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
    Joo Hyuk Sohn
    Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
    Lung Cancer 54:365-70. 2006
    ..This study was undertaken to investigate the efficacy and feasibility of combination chemotherapy of irinotecan and carboplatin in previously untreated ED-SCLC...
  24. ncbi request reprint Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
    Sun Young Rha
    Department of Internal Medicine, Cancer Metastasis Research Center, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun Ku, Seoul, Korea 120 752
    Breast Cancer Res Treat 90:215-21. 2005
    ..We evaluated the efficacy and tolerability of gemcitabine monotherapy in heavily pretreated, breast cancer patients as salvage chemotherapy...
  25. pmc A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
    Byoung Chul Cho
    Department of Yonsei Cancer Center and Internal Medicine, Yonsei University College of Medicine, 134 Seodaemun gu, Shinchon dong, Seoul 120 752, Korea
    Yonsei Med J 46:799-805. 2005
    ..No toxic death occurred. This preliminary study shows a promising and durable complete response rate with an acceptable safety profile. Further studies with greater accrual of patients are warranted...
  26. ncbi request reprint Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner
    Eunhee Kim
    BK21 Project for Medical Sciences, Institute for Cancer Research, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 120 752, Korea
    Hum Gene Ther 14:1415-28. 2003
    ....
  27. ncbi request reprint A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma
    Yong Tai Kim
    Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
    Yonsei Med J 44:539-43. 2003
    ..These findings suggest that nephrotic syndrome caused by paraneoplastic syndrome can be resolved only after the complete control of the underlying malignancy...